Grail

The companies on this list are mobilizing the creative tools of capitalism to help solve social problems.

CTW 2023-GRAIL

Early detection and diagnosis can reduce cancer mortality rates by 26%. Health care startup Grail aims to make that reduction more common with Galleri, a multicancer early detection (MCED) blood test that can detect a shared cancer signal across more than 50 types of cancers. Galleri complements physician-recommended single-cancer screenings and can help detect cancer in its early stages, when treatment is more likely to be successful.<br />
<br />
Since releasing Galleri in 2021, Grail has had over 100,000 physician orders for the test. The initiative has yet to turn a profit, but its revenue doubled in the first quarter of 2023 year over year, largely driven by test volume growth. MCED tests are not yet FDA-approved. However, Galleri was granted FDA Breakthrough Device designation in 2019, which expedites the approval process so that more patients can access the technology sooner.

Change the World

Change The World

Impact Segment

Sector

Get insights into Grail including business profile, stock information, news, and rankings from Fortune.

Grail

Grail in Fortune Rankings